Erbe Elektromedizin GmbH v. Canady Technology, LLC

512 F. Supp. 2d 297, 2007 U.S. Dist. LEXIS 15191
CourtDistrict Court, W.D. Pennsylvania
DecidedMarch 5, 2007
DocketCivil Action 05-1674
StatusPublished
Cited by2 cases

This text of 512 F. Supp. 2d 297 (Erbe Elektromedizin GmbH v. Canady Technology, LLC) is published on Counsel Stack Legal Research, covering District Court, W.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Erbe Elektromedizin GmbH v. Canady Technology, LLC, 512 F. Supp. 2d 297, 2007 U.S. Dist. LEXIS 15191 (W.D. Pa. 2007).

Opinion

CLAIMS CONSTRUCTION OPINION and ORDER

DONEATTA W. AMBROSE, Chief Judge.

I. BACKGROUND

Plaintiff Erbe Elektromedizin GmbH (“Erbe”) manufactures and sells flexible endoscopic probes for argon plasma 1 coagulation (“APC”). Erbe is the owner, by assignment, of Patent No. 5,720,745 (“Patent '745”) issued on February 24, 1998, titled “Electrosurgical Unit and Method for Achieving Coagulation of Biological Tissue.” It was filed as a continuation-in-part of Erbe’s prior Application Serial No. 981,009 (“the '009 application”), 2 and had a six year prosecution history. Plaintiff Erbe USA, Inc. is a subsidiary of Erbe. Plaintiff ConMed Corporation (“Conmed”) is in the business of manufacturing and selling electrosurgical generators and related devices, including argon gas-enhanced electrocoagulation equipment. ConMed is the owner, by assignment, of Patent No. 4,781,175 (“'175 patent”), which was issued on November 1, 1988, titled “Electrosurgical Conductive Gas Stream Technique of Achieving Improved Eschar for Coagulation.” The '175 patent was filed on April 8, 1986, by Francis T. McGreevy, Carol Bertrand, and Karl W. Hahn, and expired on April 8, 2006.

On January 21, 2000, Erbe entered into an agreement with ConMed to license several ConMed patents, including the '175 patent. Under the Agreement, Erbe was licensed to manufacture and sell various argon gas-enhanced electrocoagulation equipment, including electrosurgical generators and flexible probes related to argon gas-enhanced electrocoagulation.

Defendant Canady Technology markets and sells single use disposable flexible APC probes that may be connected to an adapter that in turn is connected to an Erbe APC electrosurgical unit. Defendant Dr. Jerome Canady is the CEO and partial owner of Canady Technology. (The Canady Defendants are hereinafter referred to as “Canady.”) Erbe has sued Canady, inter alia, for infringement of the '745 patent. (Docket No. 18, Count I). ConMed has sued Canady, inter alia, for infringement of the '175 patent. (Docket No. 18, Count II)

“Determination of patent infringement is a two-step process.” Leoutsakos v. Coll’s Hospital Pharmacy, Inc., Civ. No. 3-1533, 2004 WL 1010162 at * 2 (Fed.Cir. May 4, 2004). “First, the court determines the scope and meaning of the patent claims asserted.... ” Leoutsakos, 2004 WL 1010162 at *2, quoting, Cybor Corp. v. FAS Techs, Inc., 138 F.3d 1448, 1454 (Fed. Cir.1998). Second, the court compares the properly construed claims with the allegedly infringing device. Id.

We are at the first step of the process. The parties participated in a Markman hearing. The task now before me is to properly construe the claims in both the '745 and '175 patents.

II. GENERAL PRINCIPLES OF CLAIM CONSTRUCTION

Construction of a patent begins with the words of the claim. Vitronics Corp. v. *301 Conceptronic, Inc., 90 F.3d 1576, 1582 (Fed.Cir.1996). “[T]he words of a claim are ‘generally given their ordinary and customary meaning. Phillips v. AWH Corp., 415 F.3d 1303, 1312 (Fed.Cir.2005), quoting Vitronics, 90 F.3d at 1582. “[T]he ordinary and customary meaning of a claim term is the meaning that the term would have to a person of ordinary skill in the art in question at the time of the invention, i.e., as of the effective filing date of the patent application.” Id. at 1313, citing Innova/Pure Water, Inc. v. Safari Water Filtration Sys., Inc., 381 F.3d 1111, 1116 (Fed.Cir.2004). In cases where the terms are not readily apparent, a court will consider the intrinsic evidence and extrinsic evidence. Id. at 1314.

The intrinsic evidence consists of the claims set forth in the patent itself, together with the specifications, the embodiments and the prosecution history. Id. at 1314. “[T]he context in which a term is used in the asserted claim can be highly instructive.” Id. The specification “ ‘is the single best guide to 'the meaning of a disputed term’ ” and is usually dispositive. Id. at 1315, quoting Vitronics, 90 F.3d at 1582. Where the specification reveals a “special definition given to a claim terms by the patentee that differs from the meaning it would otherwise possess,” the inventor’s lexicography governs. Id. at 1316, citing, CCS Fitness, Inc. v. Brunswick Corp., 288 F.3d 1359, 1366 (Fed.Cir.2002). A court should also consider the prosecution history if it is in evidence. Id. at 1317, citing Markman v. Westview Instruments, Inc., 52 F.3d 967, 980 (Fed.Cir. 1995). The prosecution history, “consists of the complete record of the proceedings before the PTO and includes the prior art cited during the examination of the patent.” Id. at 1317. “[T]he prosecution history can often inform the meaning of the claim language by demonstrating how the inventor understood the invention and whether the inventor limited the invention in the course of prosecution, making the claim scope narrower than it would otherwise be.” Id., citing, Vitronics, 90 F.3d at 1582-83.

“In most situations, an analysis of the intrinsic evidence alone will resolve any ambiguity in a disputed claim term.” Vitronics, 90 F.3d at 1583. Where the ambiguities cannot be resolved by a consideration of the intrinsic evidence alone, however, the court may consider extrinsic evidence. Id. Expert testimony, dictionaries, and learned treatises are helpful sources of extrinsic evidence. Phillips, 415 F.3d at 1317. Extrinsic evidence is less significant than intrinsic evidence. Id. Thus, an expert’s testimony that is at odds with the written record of the patent should be discounted. Id. at 1318, quoting, Key Pharms. v. Hereon Labs. Corp., 161 F.3d 709, 716 (Fed.Cir.1998).

“When construing patent claims, there is a heavy presumption that the language in the claim carries its ordinary and customary meaning amongst artisans of ordinary skill in the relevant art at the time of the invention.” Housey Pharmaceuticals, Inc. v. Astrazeneca UK Ltd.,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
512 F. Supp. 2d 297, 2007 U.S. Dist. LEXIS 15191, Counsel Stack Legal Research, https://law.counselstack.com/opinion/erbe-elektromedizin-gmbh-v-canady-technology-llc-pawd-2007.